Alterity CEO to join Craig-Hallum chat October 22

Alterity says it is preparing to initiate a Phase 3 pivotal trial in MSA, a rare, rapidly progressive disease without an approved treatment.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Alterity Therapeutics Limited (ATHE) announced that David Stamler, M.D., its Chief Executive Officer, will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on October 22, 2026, at 2:30 p.m. ET. An archived webcast link will be available afterward on the company website under Investors, Events and Presentations.

Alterity says it is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA). The company says its lead asset, ATH434, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in participants with MSA, and it reported positive data from an open-label Phase 2 trial in participants with advanced MSA.

Key Figures

Conference date: October 22, 2026 Conference time: 2:30 p.m. ET Pivotal MSA trial stage: Phase 3 +2 more

5 metrics

Conference date October 22, 2026 Craig-Hallum Virtual Biotech Catalyst Conference

Conference time 2:30 p.m. ET Fireside Chat

Pivotal MSA trial stage Phase 3 Alterity says it is preparing to initiate the trial

Randomized MSA trial stage Phase 2 Trial of ATH434 in participants with MSA

Advanced MSA open-label trial stage Phase 2 Trial in participants with advanced MSA

Key Terms

Multiple System Atrophy (MSA), Phase 3 pivotal trial, randomized, double-blind, placebo-controlled Phase 2 clinical trial, open label Phase 2 clinical trial

4 terms

Multiple System Atrophy (MSA) medical

"Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

Phase 3 pivotal trial medical

"preparing to initiate a Phase 3 pivotal trial"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled Phase 2 clinical trial medical

"in a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

open label Phase 2 clinical trial medical

"in its open label Phase 2 clinical trial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Alterity (ATHE) participate in the Craig-Hallum conference?

David Stamler, M.D., Alterity’s Chief Executive Officer, will participate in a Fireside Chat on October 22, 2026, at 2:30 p.m. ET. An archived webcast link will be available afterward on the company website under Investors, Events and Presentations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 06:04 AM EDT Accepted by SEC EDGAR 10/19/2026 - 06:03 AM EDT

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1	Alterity to Present at the Craig-Hallum Biotech Conference

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited

	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: October 19, 2026

Exhibit 99.1

Alterity Therapeutics to Participate in a Fireside Chat at the

Craig-Hallum Biotech Catalyst Conference

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 19 October 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, October 22, 2026 at 2:30 p.m. ET in the United States.

A link to the archived webcast will be available after the event and can be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson’s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company’s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 EXHIBIT 99.1 7.7 KB